Get the Stockscreener App
4.06
1.93%
-0.08
After Hours:
3.98
-0.08
-1.97%
Zentalis Pharmaceuticals Inc stock is traded at $4.06, with a volume of 546.93K.
It is down -1.93% in the last 24 hours and up +5.73% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$4.14
Open:
$4.12
24h Volume:
546.93K
Relative Volume:
0.28
Market Cap:
$289.02M
Revenue:
$26.87M
Net Income/Loss:
$-137.06M
P/E Ratio:
-2.1275
EPS:
-1.9083
Net Cash Flow:
$-125.25M
1W Performance:
+0.25%
1M Performance:
+5.73%
6M Performance:
+202.99%
1Y Performance:
+227.42%
1-Day Range:
$4.00
$4.33
1-Week Range:
$3.46
$4.33
52-Week Range:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.06 | 294.71M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Presents Promising Phase 1b MUIR Trial Results of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 9 - Minichart
Zentalis to present ovarian cancer trial data at ASCO meeting By Investing.com - Investing.com Australia
Phase 1b ovarian cancer data for Zentalis (NASDAQ: ZNTL) azenosertib combo - Stock Titan
Zentalis Pharmaceuticals Announces Promising Phase 1b Results for Azenosertib Plus Paclitaxel in Ovarian Cancer at ASCO 2026 - Quiver Quantitative
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial - GlobeNewswire
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - Yahoo Finance
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
What's behind the surge in Zentalis stock? - MSN
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $5 to $10 - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.5, Implies 52% Upside - TradingView
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts - TipRanks
Zentalis Pharmaceuticals 1Q Loss/Shr 50c >ZNTL - Moomoo
TradingKey - TradingKey
Is Zentalis Pharmaceuticals (ZNTL) Attractive After Q1 2026 Earn - GuruFocus
ZNTL Advances Key Trials for Ovarian Cancer Treatment - GuruFocus
ZNTL: Azenosertib shows >30% ORR in Cyclin E1-positive PROC, targeting a major unmet need - TradingView
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zentalis Advances Azenosertib with New Trial Updates - TipRanks
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - The Manila Times
Zentalis (ZNTL) trims Q1 loss as azenosertib moves into Phase 3 - Stock Titan
Zentalis Pharmaceuticals, Inc. 1Q 2026: Net income $(35.4)M, EPS $(0.50) — 10-Q Summary - TradingView
Zentalis (Nasdaq: ZNTL) trims Q1 2026 loss while pushing azenosertib toward pivotal ovarian cancer milestones - Stock Titan
Experimental ovarian cancer pill enters Phase 3 chemo trial - Stock Titan
Zentalis Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Zentalis begins phase 3 trial of ovarian cancer drug By Investing.com - Investing.com South Africa
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial - TipRanks
Zentalis begins phase 3 trial of ovarian cancer drug - Investing.com
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis starts global Phase 3 ovarian cancer trial against chemotherapy - Stock Titan
Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC - TradingView
Phase 3 ovarian cancer trial starts for Zentalis (Nasdaq: ZNTL) drug azenosertib - Stock Titan
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Ovarian cancer drug combo data lands June ASCO presentation - Stock Titan
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Insider Monkey
ZNTL: Zentalis Presents Promising Data on Azenosertib at AACR 20 - GuruFocus
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):